Teva's strong Q2 2024 results signal financial turnaround after a decade of struggles

Read this article in:

Israel's Teva Pharmaceuticals (NYSE and TASE: TEVA) reported strong Q2 2024 results, following a decade of financial difficulties.

The Israeli pharmaceutical company reported an 11% increase in sales, reaching $4.2 billion, after a 5% growth in Q1. These promising results have led the company to be more optimistic in its annual forecast, affirming its confidence in its recovery and future growth.

Teva's recent success is particularly significant given the decline it has faced for almost ten years. The troubles began in 2015, when it attempted to acquire Mylan in a $40 billion deal. The deal fell through, resulting in a $300 million loss on the purchase of Mylan shares.

The loss was followed by the $40.5 billion acquisition of Actavis Generics from Allergan. While it was initially believed the purchase would compensate for the approaching loss of Teva’s exclusivity on its bestselling drug, Copaxone, it led to a prolonged financial strain with massive debt.

Teva’s situation worsened exponentially in 2017 when the company was forced to lay off 14,000 employees or about 25% of its global workforce. By September 2019, Teva's stock had plummeted to an all-time low, with its share value dropping by over 91%, underscoring investor concern about the company's ability to compete in the market.

In May 2023, Teva introduced a new strategy called “Pivot to Growth,” built on four key pillars. This approach aimed to enhance key products like Austedo, Ajovy, Uzedy, and biosimilars (biological medicines similar to those already approved), drive future innovation through new developments and partnerships, reinforce its position in the generic medicines market, and sharpen the business by refining product portfolios and manufacturing processes. Additionally, Teva focused on streamlining operations, reducing debt, and investing in biosimilars and specialty medicines.

On July 31, Teva issued a press release attesting to its strong Q2 2024 performance, marking the turnaround from years of struggle in the financial sector.

"2023 has been a year of significant advances for Teva, a year in which we gained momentum on our Pivot to Growth strategy and achieved strong growth in our key innovative brands, accelerated our late-stage pipeline assets, and brought our generics business back to growth,” wrote Teva CEO and President Richard Francis.

He continued: "In 2024, we look forward to seeing continued progress across our key innovative growth drivers while also executing on our high-value, complex generics business with new product launches and achieving the exciting clinical milestones of our late-stage pipeline assets."

"In the second quarter of 2024, we are encouraged by the positive momentum across each of the four pillars of our Pivot to Growth strategy. Teva's global revenues of $4.2 billion increased by 7% in U.S. dollars, or 11% in local currency terms compared to the second quarter of 2023, delivering strong growth driven mainly by our generics and innovative business, with AUSTEDO growing 32% in the U.S. compared to Q2 2023,"

He added "With these robust results, we are raising our financial guidance for 2024."

Teva's turnaround has been bolstered by favorable economic conditions and supportive market trends, along with the stabilization of the generics market and growing demand for its specialty products. While challenges remain, particularly in navigating the competitive landscape and managing its debt, Teva's recent performance suggests now it is on a solid path to recovery.